Abrocitinib
Abrocitinib, sold under the brand name Cibinqo, is a Janus kinase inhibitor medication used for the treatment of atopic dermatitis (eczema). It was developed by Pfizer.

Medical uses
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Side effects
The most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea.

Pharmacology
Mechanism of action
It is a selective inhibitor of the enzyme janus kinase 1 (JAK1).

Pharmacokinetics
Abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. Only 1.0 to 4.4% of the dose are found unmetabolized in the urine.

History
April 2016: initiation of Phase 2b trial
December 2017: initiation of JADE Mono-1 Phase 3 trial
May 2018: Results of Phase 2b trial posted
October 2019: Results of Phase 3 trial presented
June 2020: Results of second Phase 3 trial published

Society and culture
Legal status
In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cibinqo, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. In December 2021, the European Commission approved abrocitinib for the treatment of atopic dermatitis.In January 2022, the United States Food and Drug Administration (FDA) approved abrocitinib for adults with moderate-to-severe atopic dermatitis.

References
External links
"Abrocitinib". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT03349060 for "Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)" at ClinicalTrials.gov
Clinical trial number NCT03575871 for "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)" at ClinicalTrials.gov
Clinical trial number NCT03720470 for "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)" at ClinicalTrials.gov